DFTX ▲ +4.2% - Definium Therapeutics, Inc. $DFTX JPMorgan initiated coverage of Definium Therapeutics with an Overweight rating and $84 price target. The company's lead asset DT120 ODT is being developed as a treatment for various neuropsychiatric disorders, the analyst tells investors in a research note. As a psychedelic drug, JPMorgan sees DT120 ODT as potentially shifting the treatment paradigm in neuropsychiatry. It believes the asset has "intriguing pipeline-in-a-product potential." 09-OCT-2026 08:30 AM ET